Phathom Pharmaceuticals (NASDAQ:PHAT) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.38) by 79 percent. This is a 89.87 percent increase over losses of $(0.79) per share from the same period last year. The company reported quarterly sales of $57.584 million which beat the analyst consensus estimate of $57.050 million by 0.94 percent. This is a 94.12 percent increase over sales of $29.664 million the same period last year.